Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients

Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients

Author Costa-Carvalho, Beatriz Tavares Autor UNIFESP Google Scholar
Martinez, Rose Mare Alvarez Autor UNIFESP Google Scholar
Dias, Aparecida Tiemi Nagao Google Scholar
Kubo, Christiana Arslanian Google Scholar
Barros-Nunes, Patricia Autor UNIFESP Google Scholar
Leiva, Lily Google Scholar
Solé, Dirceu Autor UNIFESP Google Scholar
Carneiro-Sampaio, Magda Maria Sales Google Scholar
Naspitz, Charles Kirov Autor UNIFESP Google Scholar
Sorensen, Ricardo Uhr Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Universidade Federal do Ceará Departamento de Toxicologia e Análises Clínicas
Universidade de São Paulo (USP)
Louisiana State University Health Science Center Department of Pediatrics
Abstract The majority of children with Down syndrome (DS) tend to have frequent bacterial infections including recurrent respiratory infections. Our objective was to evaluate the production of antibodies to pneumococcal polysaccharide antigens after active immunization in DS subjects. IgG antibodies to pneumococcal serotypes (1, 3, 6B, 9V, and 14) were measured before and 6 weeks after immunization with a 23-valent pneumococcal vaccine (Pneumo23®, Pasteur-Merrieux) in 6- to 13-year-old DS children (N = 17) and in aged-matched normal controls (N = 30). An adequate response was defined as a 4-fold increase over baseline or a post-immunization level of specific pneumococcal serotype antibody> or = 1.3 µg/mL. After immunization, all DS children had an increase in post-immunization levels against all serotypes analyzed. A 4-fold or more increase was observed in all DS children concerning serotypes 1 and 14, in 90% of subjects for serotypes 3 and 9V, and in 65% for serotype 6B. Regarding this increase, 8 of the 17 DS children had an adequate response to all serotypes analyzed, 8/17 patients to 4 serotypes and 1/17 to 3 serotypes. However, when we compared post-immunization levels between DS children and controls, we observed lower levels in the former group (P < 0.05) for all serotypes except serotype 3. We conclude that pneumococcal polysaccharide immunization could be beneficial for these DS children.
Keywords Down syndrome
IgG subclass
Polysaccharide vaccine
Streptococcus pneumoniae
Pneumococcal antibodies
Language English
Date 2006-12-01
Published in Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 39, n. 12, p. 1587-1592, 2006.
ISSN 0100-879X (Sherpa/Romeo, impact factor)
Publisher Associação Brasileira de Divulgação Científica
Extent 1587-1592
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000243103300010
SciELO ID S0100-879X2006001200010 (statistics in SciELO)

Show full item record


Name: S0100-879X2006001200010.pdf
Size: 528.7Kb
Format: PDF
Open file

This item appears in the following Collection(s)




My Account